Central Hypothesis

Age‑related decline in BMAL1 expression desynchronizes not only NRF2‑mediated antioxidant defenses but also the metabolic switch from glycolysis to oxidative phosphorylation in club cells, driven by loss of BMAL1‑PPARα coupling. This dual desynchronization creates a permissive window for oxidative damage and faulty xenobiotic detoxification, pushing club cells toward a senescent, SASP‑secreting state that drives fibrosis rather than regeneration. Restoring circadian amplitude—either genetically (club‑cell‑specific BMAL1 overexpression) or pharmacologically (timed NAD⁺ boosting to enhance SIRT1‑BMAL1 activity)—will re‑align NRF2 oscillations with peak ROS and coordinate PPARα‑dependent fatty‑acid oxidation with the timing of CYP450 expression, thereby rescuing proliferative capacity and preventing fibrosis.

Mechanistic Rationale

1. BMAL1‑NRF2 axis – BMAL1 binds E‑boxes in the Nrf2 promoter, driving its circadian transcription. In aged club cells, dampened BMAL1 reduces the amplitude of Nrf2 mRNA and protein oscillations, causing antioxidant enzymes (e.g., GCLM, HO‑1) to be out‑of‑phase with mitochondrial ROS bursts that peak during the active phase.
2. BMAL1‑PPARα‑CYP450 axis – PPARα is a known BMAL1 target that governs fatty‑acid oxidation and regulates a subset of CYP450 genes (e.g., Cyp2a5, Cyp4a10). Loss of BMAL1 blunts PPARα rhythm, leading to mistimed phase‑I detoxification; toxic metabolites accumulate when antioxidant defenses are low.
3. Metabolic shift – Young club cells transition to OXPHOS during the rest phase to support repair; this shift is coordinated by BMAL1‑PPARα. Aging forces a glycolytic phenotype, increasing lactate and stabilizing HIF‑1α, which further suppresses BMAL1 transcription—a vicious loop.
4. Senescence trigger – Persistent ROS and lipid peroxidation activate p53‑p21 and p16^INK4a pathways, inducing senescence. Senescent club cells secrete IL‑6, TGF‑β, and MMPs, promoting fibroblast activation and extracellular‑matrix deposition.

Testable Predictions

• Prediction 1: In club cells from aged mice (20‑month), Bioluminescent reporters for Nrf2 and PPARα will show reduced amplitude and altered phase compared with young (3‑month) cells.
• Prediction 2: Club‑cell‑specific Bmal1 overexpression in aged mice will restore Nrf2 and PPARα oscillation amplitude (measured by qPCR time‑series) and increase the ratio of OXPHOS/glycolysis metabolites (Seahorse assay) at the anticipated circadian times.
• Prediction 3: Restored oscillation will decrease ROS accumulation (DHE staining) and lipid peroxidation (4‑HNE adducts) specifically during the expected peak ROS window, and increase NADPH‑dependent reductase activity.
• Prediction 4: Following naphthalene‑induced injury, aged mice with club‑cell‑specific Bmal1 overexpression will exhibit:
  • Higher Ki‑67⁺ club cell proliferation at 48 h post‑injury
  • Lower senescence-associated β‑galactosidase activity
  • Reduced collagen I deposition and Ashcroft score at 14 days
• Prediction 5: Pharmacological enhancement of circadian amplitude via timed NAD⁺ supplementation (e.g., NR given at ZT0) will mimic the genetic rescue, but only when administered during the subjective day; mistimed dosing will fail to improve outcomes.

Experimental Approach (Outline)

• Mouse models: Club‑cell‑specific Scgb1a1‑CreERT2; Bmal1^fl/fl (knockout) and Scgb1a1‑CreERT2; Rosa26^LSL‑Bmal1 (overexpression) crossed with a Nrf2‑luciferase reporter.
• Circadian sampling: Harvest lungs every 4 h over 24 h; perform RNA‑seq for Nrf2, PPARα, Cyp450s, and metabolic genes; measure protein levels by western blot.
• Metabolic flux: Seahorse XF analysis on isolated club cells to quantify OXPHOS vs glycolysis.
• Injury model: Single intraperitoneal naphthalene (200 mg/kg); assess regeneration and fibrosis as above.
• Intervention: NAD⁺ booster (nicotinamide riboside, 300 mg/kg) administered via oral gavage at ZT0 or ZT12 for 2 weeks pre‑injury.

Falsifiability

If club‑cell‑specific BMAL1 overexpression fails to restore Nrf2/PPARα rhythm amplitude, does not improve OXPHOS/glycolysis balance, and does not reduce senescence or fibrosis despite verified transgene expression, the hypothesis would be falsified. Similarly, if timed NAD⁺ supplementation shows no advantage over untimed dosing, the proposed circadian gating of metabolic rescue would be called into question.

Broader Impact

This hypothesis integrates circadian timing, redox biology, and metabolic reprogramming to explain why club‑cell‑centric therapies often fail in aged lungs. Success would support chronotherapeutic strategies—aligning drug administration or lifestyle interventions with endogenous rhythms—as a potent geroprotective avenue for COPD and age‑related lung fibrosis.